Fungal Infections clinical trials

Explore recruiting fungal infections clinical trials.

Recruiting fungal infections studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Fungal Infections trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1, Multicentre, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single IV Dose of Rezafungin Acetate in Paediatric Subjects from Birth to <18 Years of Age, Receiving Systemic Antifungals as Prophylaxis for Invasive Fungal Infection or to Treat a Suspected or Confirmed Fungal Infection

Germany, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

Pharmacokinetics of fluconazole given orally or intravenously as prophylaxis or therapy to children and adolescents with invasive fungal infections (FOCUS)

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 versus Standard of Care (Liposomal Amphotericin B followed by Voriconazole) for Early Antifungal Therapy of Suspected Invasive Mould Infections

Belgium, France, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species

Italy, Germany, Spain, Netherlands, Belgium, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase I/II, non randomized, monocentric open-label study of autologous CD34+ cells transduced with the G1XCGD lentiviral vector in patients with X-linked chronic granulomatous disease

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Nebulised lIposomal aMphotericin B in chronic pUlmonary aSpergillosis: a deposition study

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

Fungal Infections trials by city

Fungal Infections in Toronto Fungal Infections in Vancouver Fungal Infections in Montreal Fungal Infections in Calgary Fungal Infections in Edmonton Fungal Infections in Ottawa Fungal Infections in Winnipeg Fungal Infections in Quebec City Fungal Infections in Hamilton Fungal Infections in Kitchener Fungal Infections in London Fungal Infections in Halifax Fungal Infections in New York Fungal Infections in Los Angeles Fungal Infections in Chicago Fungal Infections in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease